DP-DCT 1.0：A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform (DP DCT)

A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform

The goal of this clinical trial is to:

1) evaluate the feasibility of conducting decentralized clinical trials (DCT) in collaboration with community resources; 2) test the reliability of a self-developed Digital Platform for Decentralized Clinical Trials (DP-DCT); and 3) compare the effect of two different glucose monitoring methods on glycemic control in patients with type 2 diabetes mellitus (T2DM). The study population consists of adults with T2DM who do not have acute diabetic complications.

The main questions it aims to answer are:

Is it feasible to conduct a DCT in collaboration with community settings across key steps such as participant recruitment, informed consent, drug delivery, and remote monitoring?

Can the DP-DCT platform reliably achieve full electronic integration from participant recruitment to statistical reporting, and automatically generate verified electronic copies of key source data in real time?

In patients taking dapagliflozin, does continuous glucose monitoring (CGM) lead to a higher rate of glycemic control target achievement compared to traditional self-monitoring of blood glucose (SMBG)?

Researchers will compare the CGM group (dapagliflozin + CGM) and the SMBG group (dapagliflozin + SMBG) to see if there is a difference in the rate of achieving glycemic control targets after 12 weeks of treatment.

Participants will:

Wear a blinded CGM device for 7days before starting treatment (run-in period) to assess eligibility for randomization.

Take dapagliflozin (10 mg once daily) and maintain healthy lifestyle habits.

Monitor their blood glucose using either a CGM device or a traditional glucose meter according to their group assignment.

Wear a smart bracelet and use a smart weight scale, with all data automatically uploaded via the DP-DCT platform.

Wear a blinded CGM device again for 7 days after the 12-week treatment period (follow-up period).

Complete most study procedures (including informed consent, drug receipt, and follow-up communication) through an online platform without frequent hospital visits, with some tasks supported by community hospitals.

Study Overview

• Status: Not yet recruiting
• Conditions: Type 2 Diabetes Mellitus (T2DM)
• Intervention / Treatment: Drug: Dapagliflozin (10mg Tab); Device: Continuous Glucose Monitoring (CGM); Other: Self-Monitoring of Blood Glucose (SMBG)

• Study Type: Interventional
• Enrollment (Estimated): 120
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Yu xia Xiang; Phone Number: 15974193674; Email: 760809010@qq.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Voluntarily agree to participate in the study and sign the informed consent form; Age between 18 and 60 years (inclusive), both genders; Diagnosed with T2DM within 5 years and have not received any glucose-lowering medication in the past 3 months, with HbA1c ≥ 7% and ≤ 9%; Willing and able to maintain a stable lifestyle in terms of diet and exercise throughout the study period; Able to properly operate a smartphone, CGM, SMBG, smart scale, and smart wristband under the guidance and training of the investigator; During the CGM run-in period, obtain at least 70% data availability from the participants.

Exclusion Criteria:

• Diagnosed with or suspected of having type 1 diabetes mellitus, monogenic diabetes, or secondary diabetes; Experienced acute complications of diabetes (diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, etc.) within 3 months prior to screening;

Severe comorbidities or medical history:

1. Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
2. Congestive heart failure (NYHA class III-IV);
3. Severe hepatic or renal impairment (ALT/AST > 3 × ULN, eGFR < 30 mL/min);
4. Malignant tumors, autoimmune diseases, severe infections, gastroparesis or other severe gastrointestinal diseases, hematological disorders;
5. History of recurrent genitourinary tract infections; Alcohol abuse or alcoholic liver disease; Known or suspected allergy to SGLT-2 inhibitors (e.g., dapagliflozin) or medical adhesives; Received glucose-lowering medication within the past 3 months; Pregnant or breastfeeding women, or women planning to become pregnant during the study period; Presence of any medical, psychological, social, or geographical factors that, in the investigator's judgment, may compromise participant safety or interfere with the assessment of study outcomes.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group A：Dapagliflozin + CGM; Initiate dapagliflozin therapy in combination with open-label CGM for glucose monitoring	Drug: Dapagliflozin (10mg Tab); 10mg，qd; Device: Continuous Glucose Monitoring (CGM); used in Group A, Open-label continuous glucose monitoring (CGM) for glucose monitoring
Experimental: Group B：Dapagliflozin + SMBG; Initiate dapagliflozin therapy in combination with SMBG for fingertip blood glucose monitoring	Drug: Dapagliflozin (10mg Tab); 10mg，qd; Other: Self-Monitoring of Blood Glucose (SMBG); Fingertip self-monitoring of blood glucose (SMBG) using glucometer

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of Participants Completing All DCT Procedures from Remote Informed Consent to Last Visit	Proportion of enrolled participants who successfully complete all predefined decentralized clinical trial (DCT) procedures, including remote informed consent, electronic data capture, device connectivity, direct-to-patient drug delivery, scheduled follow-ups, and last study visit.	through study completion, an average of 5 months
Reliability Evaluation	Implementation Rate of the DP-DCT Platform Function List: A digital intelligent clinical research platform that achieves full-process digitalization from participant recruitment to statistical reporting, along with technologies such as real-time generation of certified electronic copies of key data, must possess the following functions and meet the relevant assessment indicators.	From study start to study completion (up to 24 months)
Clinical Study Evaluation Indicators	Difference between the two groups in the change of HbA1c from baseline after 12 weeks of treatment. Change from baseline/run-in period in Time in Range (TIR, 3.9-10 mmol/L) between the two groups.	Baseline to Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Key Secondary Outcome Measure: HbA1c Key Secondary Outcome Measure	Proportion of participants in each group with HbA1c <7% after 12 weeks of treatment.	Week 12
Key Secondary Outcome Measure: HbA1c Key Secondary Outcome Measure	Proportion of participants in each group with HbA1c <6.5% after 12 weeks of treatment.	week 12
Key Secondary Outcome Measure: HbA1c Key Secondary Outcome Measure	Proportion of participants in each group with a reduction in HbA1c of ≥0.5% from baseline after 12 weeks of treatment.	week 12
Key Secondary Outcome Measure: HbA1c Key Secondary Outcome Measure	Proportion of participants in each group with a reduction in HbA1c of ≥1% from baseline after 12 weeks of treatment.	week 12
Key Secondary Outcome Measure: HbA1c Key Secondary Outcome Measure	Proportion of participants in each group with either a reduction in HbA1c of ≥1% from baseline or an HbA1c <7.0% after 12 weeks of treatment.	week 12
Key Secondary Outcome Measure: HbA1c Key Secondary Outcome Measure	Change from baseline in fasting serum glucose (FPG) after 12 weeks of treatment.	week 12
Key Secondary Outcome Measure: HbA1c Key Secondary Outcome Measure: CGM Metrics	Change from baseline/run-in period to the CGM follow-up period in Time Above Range (TAR, ≥10 mmol/L) between the two groups.	week 12
Key Secondary Outcome Measure: HbA1c Key Secondary Outcome Measure: CGM Metrics	Change from baseline/run-in period to the CGM follow-up period in Time Below Range (TBR, <3.9 mmol/L) between the two groups.	week 12
Key Secondary Outcome Measure: HbA1c Key Secondary Outcome Measure: CGM Metrics	Comparison of the coefficient of variation (CV) of glucose	week 12

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Other exploratory endpoints：Proportion of patients achieving ≥5% or ≥10% body weight reduction from baseline	Proportion of patients achieving ≥5% reduction from baseline in body weight at 12 weeks, and proportion achieving ≥10% reduction.	week 12
Other exploratory endpoints：Change from Baseline in Fasting Serum Insulin	Change from baseline in fasting serum insulin level after 12 weeks of treatment.	week 12
Other exploratory endpoints：Change from Baseline in Serum C-Peptide	Change from baseline in serum C-peptide level after 12 weeks of treatment.	week 12
Other exploratory endpoints：Change from Baseline in Glucagon	Change from baseline in glucagon level after 12 weeks of treatment.	week 12
Other exploratory endpoints：Change from Baseline in HOMA-β	Change from baseline in homeostatic model assessment of β-cell function (HOMA-β) after 12 weeks of treatment.	week 12
Other exploratory endpoints：Change from Baseline in HOMA-IR	Change from baseline in homeostatic model assessment of insulin resistance (HOMA-IR) after 12 weeks of treatment.	week 12

Collaborators and Investigators

• Sponsor: The Third Xiangya Hospital of Central South University

Study record dates

Study Major Dates

• Study Start (Estimated): August 1, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): August 1, 2027

Study Registration Dates

• First Submitted: April 27, 2026
• First Submitted That Met QC Criteria: May 12, 2026
• First Posted (Actual): May 19, 2026

Study Record Updates

• Last Update Posted (Actual): May 19, 2026
• Last Update Submitted That Met QC Criteria: May 12, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 2; Investigative Techniques; Therapeutics; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Blood Chemical Analysis; Clinical Chemistry Tests; Diagnostic Techniques, Endocrine; Monitoring, Physiologic; Self-Testing; Self Care; dapagliflozin; Continuous Glucose Monitoring; Blood Glucose Self-Monitoring
• Other Study ID Numbers: DP-DCT 1.0

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No